Are your patients connected?
In today’s fast-paced, technology-driven world, connectivity is a way of life. Medtronic’s newest hybrid closed loop system, the MiniMedTM 770G system includes apps that can help people living with diabetes stay connected with their care partners and healthcare providers, making diabetes management a little easier!
The MiniMedTM Mobile App (Figure 1) displays the patient’s insulin pump & CGM data on their smartphone and enables:
The CareLinkTM Connect App provides real-time viewing of a patient’s insulin pump and CGM data for up to 5 care partners; this can be anyone with whom the patient chooses to share this information. Care partners can receive customized alert notifications through the CareLinkTM Connect App as well as through text messaging for both pump and CGM, providing them more peace of mind.
But what if a patient isn’t using a smartphone? What if the smartphone they’re using isn’t compatible with the MiniMedTM Mobile app? In these cases, data can be uploaded to CareLinkTM personal software via the new blue adapter (Figure 2) with a laptop or desktop computer. From there, the data is then transmitted to the CareLinkTM server. This adapter, along with the CareLinkTM software uploader application 3.1.6, provides improved link detection, clearer instructions, and a fast and reliable experience for easier data uploads.
As you can see, it’s simple. The new MiniMedTM 770G system not only offers SmartGuardTM technology that adapts to patients and helps prevent highs and lows but also allows them to view their data on their smartphones, keep their loved ones in the loop and share data with their healthcare providers. It’s connected care when patients need it the most and we’re so glad it’s here!
Important Safety Information: MiniMedTM 770G System with SmartGuardTM Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G system consists of the following devices: MiniMed™ 770G insulin pump, the Guardian™ Link (3) transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu-Chek® Guide test strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library